Publications
Detailed Information
HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seo, Jeongmin | - |
dc.contributor.author | Koh, Jiwon | - |
dc.contributor.author | Lee, Dae-Won | - |
dc.contributor.author | Kim, Jinyong | - |
dc.contributor.author | Ryu, Han Suk | - |
dc.contributor.author | Lee, Kyung-Hun | - |
dc.contributor.author | Kim, Tae-Yong | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.date.accessioned | 2023-12-18T01:45:17Z | - |
dc.date.available | 2023-12-18T10:45:48Z | - |
dc.date.issued | 2023-12-14 | - |
dc.identifier.citation | Breast Cancer Research, Vol.25(1):154 | ko_KR |
dc.identifier.issn | 1465-542X | - |
dc.identifier.uri | https://hdl.handle.net/10371/198721 | - |
dc.description.abstract | Background
The role of HER2 amplification level in predicting the effectiveness of HER2-directed therapies has been established. However, its association with survival outcomes in advanced HER2-positive breast cancer treated with dual HER2-blockade remains unexplored. Methods This is a single-center retrospective study of patients with advanced HER2-positive breast cancer treated with first-line pertuzumab, trastuzumab, and docetaxel. The primary objective was to ascertain the relationship between treatment outcomes and the level of HER2 amplification by in situ hybridization (ISH). Results A total of 152 patients were included with a median follow-up duration of 50.0 months. Among the 78 patients who received ISH, a higher HER2/CEP17 ratio correlated significantly with longer PFS (HR 0.50, p = 0.022) and OS (HR 0.28, p = 0.014) when dichotomized by the median. A higher HER2 copy number also correlated significantly with better PFS (HR 0.35, p < 0.001) and OS (HR 0.27, p = 0.009). In multivariate analysis, the HER2/CEP17 ratio was an independent predictive factor for PFS (HR 0.66, p = 0.004) and potentially for OS (HR 0.64, p = 0.054), along with HER2 copy number (PFS HR 0.85, p = 0.004; OS HR 0.84, p = 0.049). Furthermore, the correlation between HER2 amplification level by ISH with PFS and OS was consistent across the HER2 IHC 1+/2+ and 3+ categories. Conclusions This is the first study to report that a higher level of HER2 amplification by ISH is associated with improved PFS and OS in advanced HER2-positive breast cancer treated with dual HER2-blockade. Notably, HER2 amplification level had a predictive role regardless of IHC results. Even in patients with HER2 protein expression of 3+, treatment outcome to HER2-directed therapy was dependent on the level of HER2 gene amplification. | ko_KR |
dc.description.sponsorship | This study was supported by Grant No. 04-2020-0500 from the Seoul National University Hospital Research Fund. This work was also supported by National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2021R1F1A1064117) | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BMC | ko_KR |
dc.subject | HER2 positive breast cancer | - |
dc.subject | HER2/CEP17 ratio | - |
dc.subject | HER2 copy number | - |
dc.subject | HER2 in situ hybridization | - |
dc.subject | Dual HER2 blockade | - |
dc.title | HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results | ko_KR |
dc.type | Article | ko_KR |
dc.identifier.doi | 10.1186/s13058-023-01746-w | ko_KR |
dc.citation.journaltitle | Breast Cancer Research | ko_KR |
dc.language.rfc3066 | en | - |
dc.rights.holder | The Author(s) | - |
dc.date.updated | 2023-12-17T04:08:55Z | - |
dc.citation.endpage | 10 | ko_KR |
dc.citation.number | 1 | ko_KR |
dc.citation.startpage | 1 | ko_KR |
dc.citation.volume | 25 | ko_KR |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.